Table 3.
Selected single nucleotide polymorphisms patient data
| SNPs | No of patients (%) | p-value | |
|---|---|---|---|
| ITP | IP | ||
| MDR1 C3435T | |||
| Polymorphisms | |||
| CT | 13 (59.1) | 14 (66.6) | 1 |
| CC | 4 (18.2) | 3 (14.3) | |
| TT | 5 (22.7) | 4 (19) | |
| MDR1 G2677 T | |||
| Polymorphisms | |||
| GT | 5 (22.7) | 5 (23.8) | 0.904 |
| GG | 15 (68.2) | 13 (61.9) | |
| TT | 2 (9.1) | 3 (14.3) | |
| ERCC1 C8092A | |||
| Polymorphisms | |||
| CA | 9 (40.9) | 8 (38.1) | 1 |
| CC | 11 (50) | 10 (47.6) | |
| AA | 2 (9.1)) | 3 (14.3) | |
| ERCC1 N118 N | |||
| Polymorphisms | |||
| CT | 8 (36.4) | 12 (57.1) | 0.371 |
| CC | 3 (13.6) | 3(14.3) | |
| TT | 11 (50) | 6 (28.6) | |
ITP Ifosfamide Paclitaxel Cisplatin, IP Ifosfamide Cisplatin